Table 2.

Patients characteristics by treatment arm and EGFR status determined on cfDNA (n=354)

	EOX arm		EOX-P arm
	EGFR non-amplified (<2)	EGFR amplified (≥2)	EGFR non-amplified (<2)	EGFR amplified (≥2)
Median age (IQR)	62.8 (56.1–68.3)	60.8 (49.8–65.3)	63.4 (55.8–69.9)	62.7 (50.2–67.1)
Males (%)	139 (85.3)	3 (75)	138 (81.7)	16 (88.9)
Females (%)	24 (14.7)	1 (25)	31 (18.3)	2 (11.1)
PS 0 (%)	70 (42.9)	2 (50)	77 (45.6)	10 (55.5)
PS 1 (%)	82 (50.3)	2 (50)	85 (50.30)	7 (38.9)
PS 2 (%)	11 (6.8)	–	7 (4.1)	1 (5.6)
Locally advanced (%)	20 (12.3)	–	26 (15.4)	2 (11.1)
Metastatic (%)	143 (87.7)	4 (100)	143 (84.6)	16 (88.9)

cfDNA, cell-free DNA; EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.